ArticleScientific reports2019
Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- An integrative review on the information and communication needs of parents of children with cancer regarding the use of complementary and alternative medicine.BMC complementary medicine and therapies · 2020Pooled it
- Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.European journal of cancer (Oxford, England : 1990) · 2024Trial
- Trial
- Use of dietary supplements and over-the-counter products among adults with a self-reported history of cancer in Poland.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Physician Partnerships and Adverse Outcomes among Breast Cancer Survivors: The Role of Adherence to Adjuvant Hormone Therapy.Journal of general internal medicine · 2026Article
- Complementary and Alternative Medicine in Oncology: A Concise Review of Utilization, Evidence, and Integration Challenges.Cancer reports (Hoboken, N.J.) · 2026Review
- Patterns and determinants of drug-drug interactions among community-dwelling older adults in Saudi Arabia: a cross-sectional study.Frontiers in pharmacology · 2026Article
- Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies.Frontiers in oncology · 2026Review
- Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors.Cancers · 2025Review
- Prevalence, associated factors, and safety implications of prehospital herbal medicine use in Southwestern, Ethiopia.Scientific reports · 2025Article
- Barriers to communication about complementary and alternative medicine between oncology patients and healthcare professionals in Croatia: a cross-sectional study.Korean journal of medical education · 2025Article
- Factors associated with herbal medicine use among patients with cancer attending a tertiary hospital in Southwestern Uganda: a cross-sectional study.Discover oncology · 2025Article
- Effect of Curcuma Longa Extract to Granzyme Expression and Tumor Mass Diameter of Mammary Adenocarcinoma with Chemotherapy Adriamycin Cyclophosphamide: An Animal Study in Rats.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- The prevalence of clinically relevant herb-drug interactions between herbal products and anti-cancer therapy in older adults with cancer - A cross-sectional study.Exploratory research in clinical and social pharmacy · 2025Article
- Cancer and Traditional Medicine: An Integrative Approach.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Prevalence and patterns of dietary supplement use and potential drug interactions among older adults in Saudi Arabia.Frontiers in pharmacology · 2025Article
- Cancer Patients' Behavior and Perception on the Use of Medical Foods and Dietary Supplements During Chemotherapy.Patient preference and adherence · 2025Article
- Unmet needs and quality of life of adult patients while receiving cancer treatment in Uganda: A cross-sectional study.PloS one · 2025Article
- Bridging the gap: attitudes and practices toward complementary and alternative medicine among oncology patients and healthcare professionals in Croatia.Frontiers in psychology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complementary medicine (CM) is used by one third to one half of cancer patients throughout the world. The objective of this study was to describe the prevalence of CM use and the potential for interactions with cancer treatments in an academic oncology centre. A cross-sectional study was conducted among patients undergoing current cancer treatment. Among 132 included patients, 56% had used CM since their cancer diagnosis and 45% were using CM during cancer treatment at the time of the survey. The main CM used were green tea (35%), herbal tea (35%), homeopathy (27%), dietary supplements (27%), and herbal medicines (27%). A small majority of patients (58%) spontaneously mentioned the use of CM to their oncologist. Of 42 identified combinations of concomitant use of biologically based CM and anticancer agents among the study patients, the potential for pharmacokinetic interactions of clinical relevance was not expected in 17 combinations (40%), hypothetical and deemed unlikely in 23 (55%), and of probable low clinical relevance in 2 (5%). Considering the high prevalence of CM use, active enquiries should be made by healthcare professionals to detect symptoms that may relate to CM tolerance and effects or that suggest interactions between CM and cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.